Hepatocellular carcinoma (HCC), the most common primary liver tumor, is notoriously
resistant to systemic therapies, and often recurs even after aggressive local therapies. HCCs …

Cancer immunotherapy (CIT) has transformed cancer treatment. In particular,
immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 …

Purpose To determine the clinical and biologic effects of bevacizumab, an anti–vascular
endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular …

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality and has an
increasing incidence worldwide. HCC can be induced by multiple etiologies, is influenced …

Nowadays, liver cancer, cirrhosis and other liver‐related diseases are the fifth most common
cause of mortality in the UK. Furthermore, chronic liver diseases (CLDs) are one of the major …

With more than half a million new cases each year, hepatocellular carcinoma (HCC) is the
fifth most common tumor worldwide and the third cause of cancer-related deaths [1]. At the …

Improved therapeutic options for hepatocellular carcinoma and metastatic disease place
greater demands on diagnostic and surveillance tests for liver disease. Existing diagnostic …

With 296 million cases estimated worldwide, chronic hepatitis B virus (HBV) infection is the
most common risk factor for hepatocellular carcinoma (HCC). HBV-encoded oncogene X …

Introduction: Persistent inflammation and hypoxia are strong stimulus for pathological
angiogenesis and vascular remodeling, and are also the most important elements resulting …

The hepatic stellate cells in the liver are stimulated sustainably by chronic injury of the
hepatocytes, activating myofibroblasts, which produce abundant collagen. Myofibroblasts …